Evofem Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $950.1K
- Price
- $0.0075
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.85%
- Volume
- 102.2K
About
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Quick stats
Shares outstanding126.7M
Computed float126.7M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001618835
Websitehttps://www.evofem.com
AI Summary
AI-generated1/5
minorbullishoperations update
Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
Evofem Biosciences announced the shipment of its 500,000th box of PHEXX, marking a cumulative commercial milestone for its hormone-free, on-demand contraceptive vaginal gel.
The company notes that this volume translates to protection for six million acts of sex, reflecting growing adoption among women seeking alternatives to hormonal contraception.
CEO Saundra Pelletier highlighted the progress while stressing the need to further educate women about the availability of non-hormonal prescription options.